Biohaven Net Income 2016-2022 | BHVN

Biohaven net income from 2016 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Biohaven Annual Net Income
(Millions of US $)
2021 $-847
2020 $-767
2019 $-529
2018 $-241
2017 $-139
2016 $-64
2015 $-10
Biohaven Quarterly Net Income
(Millions of US $)
2022-09-30 $-69
2022-06-30 $-441
2022-03-31 $-209
2021-12-31 $-317
2021-09-30 $-54
2021-06-30 $-211
2021-03-31 $-265
2020-12-31 $-218
2020-09-30 $-195
2020-06-30 $-181
2020-03-31 $-173
2019-12-31 $-149
2019-09-30 $-106
2019-06-30 $-211
2019-03-31 $-62
2018-12-31 $-55
2018-09-30 $-61
2018-06-30 $-39
2018-03-31 $-85
2017-12-31 $-27
2017-09-30 $-43
2017-06-30 $-46
2017-03-31 $-23
2016-12-31 $-26
2016-09-30 $-28
2016-06-30 $-7
2016-03-31 $-3
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.264B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00